In the SURMOUNT-4 trial, 100 patients with obesity were on tirezpatide for 9 months, and the average weight loss was 20.9 percent. The patients were then randomized to receive either placebo with behavioral intervention or tirzepatide for another year, and the patients in the former group regained a significant amount of weight. Dive further into the study’s findings and implications with Dr. John Buse and Dr. Louis Aronne, the Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medical College in New York.
Drug Delivery Systems in the Management of Diabetes
New AACE Guidelines for Treating Type 2 Diabetes
Diabetic Kidney Disease
NICE-SUGAR: Blood Glucose Levels in the ICU
Characteristics of Gestational Diabetes
Weighing Therapeutic Diets for Type 2 Diabetics
Sodium-Glucose Transporters: A New Class of Diabetes Medications
A New Paradigm for the Treatment of Type 2 Diabetes
Do Incretins Play An Important Role In the Cardiovascular System?
The Diabetes Infrastructure: Regulation & Reimbursement
New Developments in Incretins and SGLT Inhibitors
A Resurgence of Stents
What’s Happening in Hypoglycemia?
New Treatments for Peripheral Diabetic Neuropathy
Do Herbal Remedies and Vitamins Work?
Diagnosing and Treating Peripheral Arterial Disease
The Challenges of Diagnosing Diabetes in Children
Sexual Dysfunction: Communication is the Key
Common Gastrointestinal Disorders Affecting Diabetics
The Link Between Diabetes and Sleep Apnea
Create your
podcast in
minutes
It is Free
RenaissanceOnlineRadio.com
Men in Lead Aprons
Denver Underground
Exercise: Learn To Love (Or At Least Like) It
NASACast Video